FENNEC PHARMACEUTICALS INC. FENC Balance Sheet

Fennec pharmaceuticals inc. (FENC)

Balance Sheet / Yearly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Dec'10
Assets
Current assets:
Cash and cash equivalents
9,901	13,650	15,240	17,475	20,231	22,781	24,524	25,640	26,719	28,260	9,688	10,232	3,251	3,926	4,537	5,081	545	942	1,366	1,854	1,916	2,307	593	1,015	1,338	1,663	538	1,007	1,896	2,303	2,860	3,586	4,719	5,297	6,174	6,810	5,947
Prepaid expenses
220	226	387	56	108	168	411	60	107	128	198	21	32	43	41	18	40	76	83	14	31	48	67	25	54	81	101	20	39	56	64	11	24	35	82	12	38
Other current assets
2	8	-	1	4	1	0	4	10	13	2	6	5	3	2	5	3	1	1	3	2	17	13	9	3	8	1	3	3	6	6	3	14	19	15	8	8
Total current assets
10,123	13,884	15,627	17,532	20,343	22,950	24,935	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-current assets:
Deferred issuance costs
326	326	326	326	326	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of deferred issuance costs
81	64	46	29	12	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total non-current assets
245	262	280	297	314	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total assets
10,368	14,146	15,907	17,829	20,657	22,950	-	25,704	26,836	28,401	9,888	10,259	3,288	3,972	4,580	5,104	588	1,019	1,450	1,871	1,949	2,372	673	1,049	1,395	1,752	640	1,030	1,938	2,365	2,930	3,600	4,757	5,351	6,271	6,830	5,993
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
1,675	1,612	788	1,228	1,298	1,032	1,866	709	1,033	855	492	296	224	244	235	345	225	297	252	401	384	308	364	335	154	212	315	716	698	259	315	276	374	342	414	239	272
Accrued liabilities
232	659	117	125	153	605	210	138	140	622	165	94	132	125	88	50	81	92	86	49	45	132	38	36	57	132	65	65	92	423	87	173	38	52	62	31	195
Derivative instruments (Note 5)
-	-	-	-	-	-	0	0	0	167	373	190	71	33	37	56	39	82	93	309	694	1,319	3,499	5,336	5,518	2,863	4,387	2,678	10,213	6,640	1,244	1,106	1,750	5,077	9,465	7,244	-
Total current liabilities
1,907	2,271	905	1,353	1,451	1,637	2,076	847	1,173	1,644	1,030	580	427	402	360	451	345	471	431	759	1,123	1,759	3,901	5,707	5,729	3,207	-	-	11,003	7,322	-	-	-	5,471	-	-	10,917
Total liabilities
-	-	-	-	-	1,637	2,076	847	1,173	1,644	1,030	580	427	402	360	451	345	471	431	759	1,123	1,759	3,901	5,707	5,729	3,207	4,767	3,459	11,003	7,322	1,646	1,555	2,162	5,471	9,941	7,514	10,917
Commitments and Contingencies (Note 9)
-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders' equity:
Common stock, no par value; unlimited shares authorized; 19,896 shares issued and outstanding (2019-19,896)
106,392	106,392	106,392	106,392	106,392	106,392	104,770	104,010	103,337	103,045	83,062	82,277	74,515	74,515	74,261	74,261	69,255	69,401	69,153	69,132	68,683	68,656	66,790	66,790	66,790	66,790	65,952	65,952	65,952	65,952	65,952	65,952	65,952	65,952	65,952	65,952	64,929
Additional paid-in capital
48,683	48,271	47,788	47,453	45,453	44,934	45,118	45,127	44,019	43,837	43,631	42,885	42,231	42,134	41,895	41,826	41,698	41,437	41,616	41,607	41,597	41,588	41,001	39,951	39,525	39,210	38,488	38,420	38,391	38,391	38,120	38,117	38,065	38,065	38,021	37,863	37,717
Accumulated deficit
-147,857	-144,031	-140,421	-138,612	-133,882	-131,256	-128,272	-125,523	-122,936	-121,368	-119,078	-116,726	-115,128	-114,322	-113,179	-112,677	-111,953	-111,533	-110,993	-110,870	-110,697	-110,874	-	-	-	-108,698	-	-	-	-	-	-	-	-	-	-	-
Deficit accumulated during development stage
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	112,262	112,642	111,892	-	109,810	108,044	114,651	110,543	104,031	103,267	102,665	105,380	108,886	105,742	108,813
Accumulated other comprehensive income
1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243	1,243
Total stockholders' equity
8,461	11,875	15,002	16,476	19,206	21,313	22,859	24,857	25,663	26,757	8,858	9,679	2,861	3,570	4,220	4,653	243	548	1,019	1,112	826	613	-3,228	-4,658	-4,334	-1,455	-4,127	-2,429	-9,065	-4,957	1,284	2,045	2,595	-120	-3,670	-684	-4,924
Total liabilities and stockholders' equity
10,368	14,146	15,907	17,829	20,657	22,950	24,935	25,704	26,836	28,401	9,888	10,259	3,288	3,972	4,580	5,104	588	1,019	1,450	1,871	1,949	2,372	673	1,049	1,395	1,752	640	1,030	1,938	2,365	2,930	3,600	4,757	5,351	6,271	6,830	5,993